Liquidia Technologies Stock Earnings Reports

Liquidia reported strong commercial momentum for YUTREPIA in Q1 2026, highlighting category leadership in inhaled prostacyclins and rapid adoption across centers and community prescribers. Key commercial metrics: ~4,500 unique prescriptions and ~3,750 patient starts since launch (as of April 30), ~980 prescribing physicians, and growing depth of prescribing (physicians with 5+ patients up ~25% since February). Financial performance was robust: Q1 net product sales of $129.9M (up 44% sequentially vs Q4 2025), third consecutive profitable quarter, net income ~$52.9M, adjusted EBITDA ~$71.2M, and $222.8M cash on hand. Management emphasizes a self-funded model, reinvesting operating cash flow into manufacturing expansion, commercial/sales force growth, and clinical development. Clinical pipeline and investment: ongoing recruitment for ASCENT Cohort B (transitions from Tyvaso DPI), pivotal Phase III RESPIRE study for L606 (twice-daily liposomal treprostinil) with the intent to improve tolerability/dosing and enable broader indications/usage, and exploratory programs targeting IPF, PPF, PH-COPD and scleroderma-associated Raynaud's phenomenon. Management reiterated confidence in market opportunity (PAH + PH-ILD and potential additional indications), noting an annualized net revenue run rate for YUTREPIA exceeding $0.5B in <1 year and a clear line of sight to at least $1B in net revenue in 2027. Legal/regulatory: management sees some parallels between Liquidia’s ongoing litigation and the Hikma case but will not speculate on timing or outcome; they remain confident in their legal position. Overall takeaways for investors: accelerating commercial adoption, strong quarter-over-quarter revenue and profit growth, solid cash balance supporting self-funded expansion, multiple clinical catalysts ahead (ASCENT, RESPIRE, transition studies), and an aggressive vision to expand the franchise into additional pulmonary/vascular indications.